Microvessel mechanobiology in pulmonary arterial hypertension

Hypertension

Volumn 65, Issue 3, 2015, Pages 483-489

  Bloodworth, Nathaniel C ^a   West, James D ^a   Merryman, W David ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; ELASTIN;

ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ARTICLE; BIOACCUMULATION; BIOMECHANICS; BLOOD VESSEL PARAMETERS; CELL FUNCTION; CELLULAR PARAMETERS; COLLAGEN SYNTHESIS; DISEASE COURSE; DISEASES; EXTRACELLULAR MATRIX; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE WORK; HUMAN; MECHANOTRANSDUCTION; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERIOLAR COMPLIANCE; PULMONARY HYPERTENSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; VASCULAR REMODELING; HEART VENTRICLE; LUNG; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY ARTERY; VASCULAR RESISTANCE; VASCULARIZATION;

BIOMECHANICAL PHENOMENA; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; HEART VENTRICLES; HUMANS; HYPERTENSION, PULMONARY; LUNG; MICROVESSELS; PULMONARY ARTERY; SIGNAL TRANSDUCTION; VASCULAR RESISTANCE;

EID: 84924245213     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04652     Document Type: Article

References (57)

1. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012;122:4306-4313. doi: 10.1172/JCI60658.
2. Sutendra G, Michelakis ED. Pulmonary arterial hypertension: challenges in translational research and a vision for change. Sci Transl Med. 2013;5:208sr5. doi: 10.1126/scitranslmed.3005428.
3. Lammers S, Scott D, Hunter K, Tan W, Shandas R, Stenmark KR. Mechanics and function of the pulmonary vasculature: implications for pulmonary vascular disease and right ventricular function. Compr Physiol. 2012;2:295-319. doi: 10.1002/cphy.c100070.
4. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol. 2006;47:799-803. doi: 10.1016/j.jacc.2005.09.054.
5. Brittain EL, Pugh ME, Wheeler LA, Robbins IM, Loyd JE, Newman JH, Larkin EK, Austin ED, Hemnes AR. Shorter survival in familial versus idiopathic pulmonary arterial hypertension is associated with hemodynamic markers of impaired right ventricular function. Pulm Circ. 2013;3:589-598. doi: 10.1086/674326.
6. Saouti N, Westerhof N, Helderman F, Marcus JT, Stergiopulos N, Westerhof BE, Boonstra A, Postmus PE, Vonk-Noordegraaf A. RC time constant of single lung equals that of both lungs together: a study in chronic thromboembolic pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2009;297:H2154-H2160. doi: 10.1152/ajpheart.00694.2009.
7. Chelladurai P, Seeger W, Pullamsetti SS. Matrix metalloproteinases and their inhibitors in pulmonary hypertension. Eur Respir J. 2012;40:766-782. doi: 10.1183/09031936.00209911.
8. Hunter KS, Lee PF, Lanning CJ, Ivy DD, Kirby KS, Claussen LR, Chan KC, Shandas R. Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension. Am Heart J. 2008;155:166-174. doi: 10.1016/j.ahj.2007.08.014.
9. Saouti N, Westerhof N, Helderman F, Marcus JT, Boonstra A, Postmus PE, Vonk-Noordegraaf A. Right ventricular oscillatory power is a constant fraction of total power irrespective of pulmonary artery pressure. Am J Respir Crit Care Med. 2010;182:1315-1320. doi: 10.1164/rccm.200910-1643OC.
10. Mitchell GF. Arterial stiffness and hypertension: chicken or egg? Hypertension. 2014;64:210-214. doi: 10.1161/HYPERTENSIONAHA.114.03449.
11. Mahapatra S, Nishimura RA, Oh JK, McGoon MD. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr. 2006;19:1045-1050. doi: 10.1016/j.echo.2006.03.008.
12. Lalande S, Yerly P, Faoro V, Naeije R. Pulmonary vascular distensibility predicts aerobic capacity in healthy individuals. J Physiol. 2012;590:4279-4288.
13. Reusser M, Hunter KS, Lammers SR, Stenmark KR. Validation of a pressure diameter method for determining modulus and strain of collagen engagement for long branches of bovine pulmonary arteries. J Biomech Eng. 2012;134:054501. doi: 10.1115/1.4006686.
14. Linehan JH, Haworth ST, Nelin LD, Krenz GS, Dawson CA. A simple distensible vessel model for interpreting pulmonary vascular pressureflow curves. J Appl Physiol (1985). 1992;73:987-994.
15. Lankhaar J-W, Westerhof N, Faes TJC, Gan CT-J, Marques KM, Boonstra A, van den Berg FG, Postmus PE, Vonk-Noordegraaf A. Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. Eur Heart J. 2008;29:1688-1695.
16. Birukova AA, Tian X, Cokic I, Beckham Y, Gardel ML, Birukov KG. Endothelial barrier disruption and recovery is controlled by substrate stiffness. Microvasc Res. 2013;87:50-57. doi: 10.1016/j.mvr.2012.12.006.
17. Gupta V, Grande-Allen KJ. Effects of static and cyclic loading in regulating extracellular matrix synthesis by cardiovascular cells. Cardiovasc Res. 2006;72:375-383. doi: 10.1016/j.cardiores.2006.08.017.
18. Scott D, Tan Y, Shandas R, Stenmark KR, Tan W. High pulsatility flow stimulates smooth muscle cell hypertrophy and contractile protein expression. Am J Physiol Lung Cell Mol Physiol. 2013;304:L70-L81. doi: 10.1152/ajplung.00342.2012.
19. Li M, Tan Y, Stenmark KR, Tan W. High pulsatility flow induces acute endothelial inflammation through overpolarizing cells to activate NF-êB. Cardiovasc Eng Technol. 2013;4:26-38. doi: 10.1007/s13239-012-0115-5.
20. Botney MD, Liptay MJ, Kaiser LR, Cooper JD, Parks WC, Mecham RP. Active collagen synthesis by pulmonary arteries in human primary pulmonary hypertension. Am J Pathol. 1993;143:121-129.
21. Chow MJ, Turcotte R, Lin CP, Zhang Y. Arterial extracellular matrix: a mechanobiological study of the contributions and interactions of elastin and collagen. Biophys J. 2014;106:2684-2692. doi: 10.1016/j.bpj.2014.05.014.
22. Kobs RW, Chesler NC. The mechanobiology of pulmonary vascular remodeling in the congenital absence of eNOS. Biomech Model Mechanobiol. 2006;5:217-225. doi: 10.1007/s10237-006-0018-1.
23. Rogers NM, Yao M, Sembrat J, George MP, Knupp H, Ross M, Sharifi-Sanjani M, Milosevic J, St Croix C, Rajkumar R, Frid MG, Hunter KS, Mazzaro L, Novelli EM, Stenmark KR, et al. Cellular, pharmacological, and biophysical evaluation of explanted lungs from a patient with sickle cell disease and severe pulmonary arterial hypertension. Pulm Circ. 2013;3:936-951.
24. Sakao S, Tatsumi K, Voelkel NF. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir Res. 2009;10:95. doi: 10.1186/1465-9921-10-95.
25. Sokolis DP, Kefaloyannis EM, Kouloukoussa M, Marinos E, Boudoulas H, Karayannacos PE. A structural basis for the aortic stress-strain relation in uniaxial tension. J Biomech. 2006;39:1651-1662. doi: 10.1016/j.jbiomech.2005.05.003.
26. Lepetit H, Eddahibi S, Fadel E, Frisdal E, Munaut C, Noel A, Humbert M, Adnot S, D'Ortho MP, Lafuma C. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J. 2005;25:834-842. doi: 10.1183/09031936.05.00072504.
27. Safdar Z, Tamez E, Chan W, Arya B, Ge Y, Deswal A, Bozkurt B, Frost A, Entman M. Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension. JACC Heart Fail. 2014;2:412-421.doi: 10.1016/j.jchf.2014.03.013.
28. Matsui K, Takano Y, Yu ZX, Hi JE, Stetler-Stevenson WG, Travis WD, Ferrans VJ. Immunohistochemical study of endothelin-1 and matrix metalloproteinases in plexogenic pulmonary arteriopathy. Pathol Res Pract. 2002;198:403-412. doi: 10.1078/0344-0338-00273.
29. Agrotis A. The genetic basis for altered blood vessel function in disease: large artery stiffening. Vasc Health Risk Manag. 2005;1:333-344.
30. Shifren A, Durmowicz AG, Knutsen RH, Faury G, Mecham RP. Elastin insufficiency predisposes to elevated pulmonary circulatory pressures through changes in elastic artery structure. J Appl Physiol (1985). 2008;105:1610-1619. doi: 10.1152/japplphysiol.90563.2008.
31. Durmowicz AG, Parks WC, Hyde DM, Mecham RP, Stenmark KR. Persistence, re-expression, and induction of pulmonary arterial fibronectin, tropoelastin, and type I procollagen mRNA expression in neonatal hypoxic pulmonary hypertension. Am J Pathol. 1994;145:1411-1420.
32. Kim YM, Haghighat L, Spiekerkoetter E, Sawada H, Alvira CM, Wang L, Acharya S, Rodriguez-Colon G, Orton A, Zhao M, Rabinovitch M. Neutrophil elastase is produced by pulmonary artery smooth muscle cells and is linked to neointimal lesions. Am J Pathol. 2011;179:1560-1572. doi: 10.1016/j.ajpath.2011.05.051.
33. Timmins LH, Wu Q, Yeh AT, Moore JE Jr, Greenwald SE. Structural inhomogeneity and fiber orientation in the inner arterial media. Am J Physiol Heart Circ Physiol. 2010;298:H1537-H1545. doi: 10.1152/ajpheart.00891.2009.
34. Vanderpool RR, El-Bizri N, Rabinovitch M, Chesler NC. Patchy deletion of Bmpr1a potentiates proximal pulmonary artery remodeling in mice exposed to chronic hypoxia. Biomech Model Mechanobiol. 2013;12:33-42. doi: 10.1007/s10237-012-0379-6.
35. Long L, Crosby A, Yang X, Southwood M, Upton PD, Kim DK, Morrell NW. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation. 2009;119:566-576. doi: 10.1161/CIRCULATIONAHA.108.821504.
36. Groth A, Vrugt B, Brock M, Speich R, Ulrich S, Huber LC. Inflammatory cytokines in pulmonary hypertension. Respir Res. 2014;15:47. doi: 10.1186/1465-9921-15-47.
37. Thomas M, Ciuclan L, Hussey MJ, Press NJ. Targeting the serotonin pathway for the treatment of pulmonary arterial hypertension. Pharmacol Ther. 2013;138:409-417. doi: 10.1016/j.pharmthera.2013.02.002.
38. Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A, Jüngel A, Beyer C, Krönke G, Zwerina J, Reiter R, Alenina N, Maroteaux L, Gay S, Schett G, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med. 2011;208:961-972.
39. Launay JM, Hervé P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med. 2002;8:1129-1135. doi: 10.1038/nm764.
40. Penumatsa KC, Fanburg BL. Transglutaminase 2-mediated serotonylation in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2014;306:L309-L315. doi: 10.1152/ajplung.00321.2013.
41. Greenway S, van Suylen RJ, Du Marchie Sarvaas G, Kwan E, Ambartsumian N, Lukanidin E, Rabinovitch M. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol. 2004;164:253-262. doi: 10.1016/S0002-9440(10)63115-X.
42. Lawrie A, Spiekerkoetter E, Martinez EC, Ambartsumian N, Sheward WJ, MacLean MR, Harmar AJ, Schmidt AM, Lukanidin E, Rabinovitch M. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res. 2005;97:227-235. doi: 10.1161/01.RES.0000176025.57706.1e.
43. Gao YZ, Saphirstein RJ, Yamin R, Suki B, Morgan KG. Aging impairs smooth muscle-mediated regulation of aortic stiffness: a defect in shock absorption function? Am J Physiol Heart Circ Physiol. 2014;307:H1252-H1261. doi: 10.1152/ajpheart.00392.2014.
44. Umesh A, Paudel O, Cao Y-N, Myers AC, Sham JSK. Alteration of pulmonary artery integrin levels in chronic hypoxia and monocrotaline-induced pulmonary hypertension. J Vasc Res. 2011;48:525-537.
45. Wong WKP, Knowles JA, Morse JH. Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2005;33:438-446.
46. Min J, Reznichenko M, Poythress RH, Gallant CM, Vetterkind S, Li Y, Morgan KG. Src modulates contractile vascular smooth muscle function via regulation of focal adhesions. J Cell Physiol. 2012;227:3585-3592. doi: 10.1002/jcp.24062.
47. Paulin R, Meloche J, Courboulin A, Lambert C, Haromy A, Courchesne A, Bonnet P, Provencher S, Michelakis ED, Bonnet S. Targeting cell motility in pulmonary arterial hypertension. Eur Respir J. 2014;43:531-544. doi: 10.1183/09031936.00181312.
48. Pullamsetti SS, Berghausen EM, Dabral S, Tretyn A, Butrous E, Savai R, Butrous G, Dahal BK, Brandes RP, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Rosenkranz S, Schermuly RT. Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2012;32:1354-1365. doi: 10.1161/ATVBAHA.112.248500.
49. Saphirstein RJ, Gao YZ, Jensen MH, Gallant CM, Vetterkind S, Moore JR, Morgan KG. The focal adhesion: a regulated component of aortic stiffness. PLoS One. 2013;8:e62461. doi: 10.1371/journal.pone.0062461.
50. Martinez-Lemus LA, Hill MA, Bolz SS, Pohl U, Meininger GA. Acute mechanoadaptation of vascular smooth muscle cells in response to continuous arteriolar vasoconstriction: implications for functional remodeling. FASEB J. 2004;18:708-710. doi: 10.1096/fj.03-0634fje.
51. Sehgel NL, Zhu Y, Sun Z, Trzeciakowski JP, Hong Z, Hunter WC, Vatner DE, Meininger GA, Vatner SF. Increased vascular smooth muscle cell stiffness: a novel mechanism for aortic stiffness in hypertension. Am J Physiol Heart Circ Physiol. 2013;305:H1281-H1287. doi: 10.1152/ajpheart.00232.2013.
52. Gunst SJ, Zhang W. Actin cytoskeletal dynamics in smooth muscle: a new paradigm for the regulation of smooth muscle contraction. Am J Physiol Cell Physiol. 2008;295:C576-C587. doi: 10.1152/ajpcell.00253.2008.
53. Johnson JA, Hemnes AR, Perrien DS, Schuster M, Robinson LJ, Gladson S, Loibner H, Bai S, Blackwell TR, Tada Y, Harral JW, Talati M, Lane KB, Fagan KA, West J. Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2012;302:L474-L484. doi: 10.1152/ajplung.00202.2011.
54. Yasuda T, Tada Y, Tanabe N, Tatsumi K, West J. Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene. Am J Physiol Lung Cell Mol Physiol. 2011;301:L667-L674. doi: 10.1152/ajplung.00423.2010.
55. Foletta VC, Lim MA, Soosairajah J, Kelly AP, Stanley EG, Shannon M, He W, Das S, Massague J, Bernard O, Soosairaiah J. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J Cell Biol. 2003;162:1089-1098. doi: 10.1083/jcb.200212060.
56. Edwards DC, Sanders LC, Bokoch GM, Gill GN. Activation of LIMkinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol. 1999;1:253-259. doi: 10.1038/12963.
57. Morrell NW, Archer SL, Defelice A, Evans S, Fiszman M, Martin T, Saulnier M, Rabinovitch M, Schermuly R, Stewart D, Truebel H, Walker G, Stenmark KR. Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm Circ. 2013;3:226-244. doi: 10.4103/2045-8932.109940.